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Dendritic cells (DCs) are potent modulators of im-
mune responses. In addition to their classical role as ef-
ficient antigen (Ag)-presenting cells and initiators of T 
cell responses, DCs can also suppress such responses 
and induce a state of immunological tolerance to Ags 
(Steinman 2012). It has been shown under several con-
ditions that Ag presentation by DCs with an immature 
phenotype leads to either no response or tolerization to 
specific Ags, whereas Ag presentation by mature DC re-
sults in T cell proliferation and differentiation of effector 
functions. Because these cells only achieve full immu-
nostimulatory capacity upon maturation, the selection of 
maturation factors becomes very important when DCs 
are derived in vitro (Steinman 2012).
Regarding maturation factors, prostaglandin E2 
(PGE2), a lipid molecule released during inflamma-
tion, is typically the maturation factor of choice due 
to its ability to potentiate the effect of tumour necrosis 
factor-alpha (TNF-α), stimulate interleukin (IL)-12 and 
increase chemokine receptor 7 expression (Rieser et al. 
1997, Prechtel et al. 2007). Another factor that has been 
used to mature DCs is Bacillus Calmette-Guérin (BCG), 
which acts through the activation of Toll-like receptors 
(TLRs) in a manner similar to lipopolysaccharide (LPS) 
(Tsuji et al. 2000).
However, certain molecules can also interfere with 
the efficiency of DC maturation, one of which is the pro-
angiogenic vascular endothelial growth factor (VEGF), 
a soluble factor that is produced constitutively by nearly 
all types of solid tumours and stimulates both the growth 
of endothelial cells and new vessel formation. It has been 
shown that VEGF causes defective DC differentiation 
and maturation (Gabrilovich et al. 1998, Menetrier-Caux 
et al. 1998, Oyama et al. 1998, Zhang et al. 2003, Taka-
hashi et al. 2004). Moreover, the addition of VEGF to DC 
cultures promotes a weak stimulus for Ag-specific T cells 
due to an inhibitory effect mediated by VEGF receptor 
1 (VEGFR1)/Flt-1 signalling (Nemeth et al. 2004, Lax-
manan et al. 2005). Of the described receptors for VEGF, 
VEGFR1 is the primary mediator of DC maturation in-
hibition (Dikov et al. 2005), whereas VEGFR2 is respon-
sible for signal transduction in mature DCs, activating 
extracellular signal-regulated protein kinases 1 and 2 and 
impairing the DC stimulation of allogeneic lymphocytes 
(Kadambi et al. 2001, Mimura et al. 2007).
Another molecule involved in tolerogenesis is the 
enzyme indoleamine 2,3-dioxygenase (IDO), which is 
produced by many cell types, including DCs. The acti-
vation of IDO, mainly by interferon-γ, reduces the avail-
able concentration of its substrate tryptophan, which is 
essential for T cell proliferation (Mellor & Munn 2004). 
However, independently of its activation, IDO can also 
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Dendritic cells (DCs) are antigen (Ag)-presenting cells that activate and stimulate effective immune responses by 
T cells, but can also act as negative regulators of these responses and thus play important roles in immune regula-
tion. Pro-angiogenic vascular endothelial growth factor (VEGF) has been shown to cause defective DC differentia-
tion and maturation. Previous studies have demonstrated that the addition of VEGF to DC cultures renders these 
cells weak stimulators of Ag-specific T cells due to the inhibitory effects mediated by VEGF receptor 1 (VEGFR1) 
and/or VEGFR2 signalling. As the enzyme indoleamine 2,3-dioxygenase (IDO) is recognised as an important nega-
tive regulator of immune responses, this study aimed to investigate whether VEGF affects the expression of IDO 
by DCs and whether VEGF-matured DCs acquire a suppressor phenotype. Our results are the first to demonstrate 
that VEGF increases the expression and activity of IDO in DCs, which has a suppressive effect on Ag-specific and 
mitogen-stimulated lymphocyte proliferation. These mechanisms have broad implications for the study of immuno-
logical responses and tolerance under conditions as diverse as cancer, graft rejection and autoimmunity.
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act as a signal transducer in response to TGF-β and 
confer a stable tolerogenic phenotype to plasmacytoid 
DCs, which in turn stimulate Tregs, thereby maintaining 
a state of tolerance (Chen 2011, Pallotta et al. 2011). A 
variety of conditions are finely tuned by IDO, ranging 
from pregnancy (Munn et al. 1998) and transplantation 
(Lan et al. 2010) to autoimmunity (Platten et al. 2005) 
and neoplasia (Katz et al. 2008).
Tumour microenvironments are naturally rich in 
immunomodulatory molecules that can interfere with 
DC maturation and prevent the development of effec-
tive anti-tumour responses (Lorusso & Rüegg 2008). 
Therefore, it is important to identify the molecules and 
underlying mechanisms of a non-response, as they can 
also be important in other conditions, such as graft re-
jection and autoimmunity (Almand et al. 2000, Wood 
et al. 2010).
Although a role for VEGF in defective DC function 
has been suggested and immunological tolerance induc-
tion by IDO expression is well accepted, no studies have 
verified whether VEGF affects IDO expression levels or 
activity. Accordingly, in the present study, we investigat-
ed the effect of VEGF on IDO expression levels and its 
activity with regard to DC maturation and lymphocytic 
proliferation.
MATERIALS AND METHODS
Peripheral blood collection and CD14+ cell isolation 
- Peripheral blood was obtained from healthy volunteers 
after providing informed written consent according to 
the Ethical Research Committee or Israel Institute of 
Education and Research (105/02). Mononuclear cells 
were purified from the peripheral blood using density 
gradient Ficoll-PaqueTM Plus (GE Healthcare, Bucking-
hamshire, UK) according the manufacturer’s instruc-
tions. The CD14+ cell population was isolated from the 
mononuclear fraction by magnetic bead separation ac-
cording to the manufacturer’s protocol (Miltenyi Biotec, 
Bergisch Gladbach, Germany).
DC generation and treatment with VEGF A - The 
CD14+ cell population was dispensed into six-well plates 
containing X-vivo 15 medium (Cambrex, Walkersville, 
MD, USA) supplemented with antibiotic-antimycoticsTM 
(Gibco, North Andover, MA, USA). To generate imma-
ture DCs, the cells were cultured in the presence of 20 
ng/mL recombinant IL-4 (rIL-4) (R&D System) and 50 
ng/ml rGM-CSF (R&D System) for six days (D6). Ma-
ture DCs were obtained after 24 h (D7) of stimulation of 
the immature DC culture with 10 ng/mL rTNF-α (R&D 
System) plus 0.01 mmol/L PGE2 (Sigma, St. Louis, MO, 
USA), referred to in this paper as PG-TNF; the concen-
trations used were previously described (Szabolcs et al. 
2004). Alternatively, the immature DC cultures were 
stimulated to maturity by adding 20 µg BCG (Ataulpho 
de Paiva Foundation, Rio de Janeiro, Brazil). The BCG 
suspension was previously titrated to obtain the lowest 
dose capable of stimulating efficient DC maturation 
(data not shown).
To study the effect of VEGF on DCs, the cells were 
cultivated after the initial day of culture in the presence 
or absence of 20 ng/mL of human rVEGF A, isoform165 
(Calbiochem-Millipore, Billerica, MA, USA), which it 
the predominant form of VEGF during angiogenesis.
Flow cytometry analysis - Staining of the cells for 
flow cytometry analyses was performed using commer-
cially available monoclonal antibodies (mAbs) accord-
ing to the manufacturer’s instructions. Briefly, the cells 
were stained with the selected mAbs and incubated in 
the dark for 30 min at room temperature. The cells were 
then washed and fixed with 1% paraformaldehyde, with 
the exception of the cells tested for apoptosis, which 
were resuspended in the Annexin V binding buffer (BD 
Pharmingen, San Diego, CA, USA) provided with the 
reagent set. Intracellular staining was performed in pre-
viously fixed and permeabilised surface-stained cells 
prior to adding the labelled intracellular mAb.
The mAbs used to evaluate DC markers or matu-
ration were as follows: CD11c-PE clone:B-ly6, CD14-
fluorescein isothiocyanate (FITC) clone:M5E2, CD80-
PE clone:L307.4, CD83-PE clone:HB15e, CD86-PE 
clone:2331, CD123-PE clone:9F5 and CD209-PE 
clone:DCN46 (all purchased from BD Pharmingen); 
HLA-DR-PerCP-Cy5.5 clone:L243 and isotype controls 
(purchased from BD Biosciences, San Jose, CA, USA).
To assess lymphocyte proliferation, we used Ki-67-
FITC clone:B56 and CD3-PerCP Cy5.5 clone:SK7 in ad-
dition to isotype controls (BD Biosciences).
Monoclonal Abs against the VEGF receptors, in-
cluding anti-VEGFR1-pure clone:49560 and VEGFR2-
PE clone:89106 (R&D System) and VEGFR3-pure 
clone:9D9F9 (Chemicon, Temecula, CA, USA) and iso-
type controls were also used.
Rabbit anti-human IDO polyclonal antibody was pur-
chased from Chemicon. Annexin V-FITC, propidium io-
dide, anti-caspase-3 active form-PE and isotype controls 
were purchased from BD Pharmingen. The secondary 
Abs included goat anti-mouse-FITC, goat anti-rabbit-
FITC and sheep anti-mouse-PE and were purchased 
from Chemicon.
The data were acquired using the FACSARIA flow 
cytometer (BD Biosciences) and the analyses were per-
formed using the FACSDIVA software (BD Biosciences) 
and/or FLOWJO (Tree Star, Ashland, OR, USA).
Ag-specific proliferation assay - Mature DCs cul-
tured in the presence or absence of VEGF (104 cells/100 
µL) were co-cultivated in 96-well tissue culture plates 
(BD Biosciences-Discovery Labware, San Jose, CA, 
USA) for four days with autologous lymphocytes (105 
cells/100 µL) previously stained with 5 µM/mL of car-
boxyfluorescein succinimidyl ester (CFSE) (Invitrogen). 
Ag-specific stimulation was performed by priming the 
DCs with lyophilised Candida albicans (10 µg/mL) and 
non-specific stimulation of the cultures was performed 
by adding the mitogen phytohaemagglutinin (PHA) 1 
µg/mL). The DCs were γ-irradiated at 1,500 rads (Gam-
maCell 1000 137Cs source) prior to co-cultivation.
After four days in culture, lymphocyte proliferation 
was monitored according to the CFSE fluorescence lev-
els in the 530/30 channel. The lymphocyte populations 
were gated by size and granularity [side light scatter 
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(SSC) vs. forward light scatter (FSC)] and the events se-
lected in the lymphocyte gate were analysed in a second 
plot (histogram). The data analyses were performed us-
ing the FLOWJO software. The results were expressed 
using the division index, which represents the average 
number of divisions that a cell has undergone.
We also analysed non-specific (PHA) lymphocyte 
proliferation in co-cultures arranged as described, in 
which a specific inhibitor of IDO, 1-methyl-D-trypto-
phan (1-MT) at 1 mM (Aldrich, St. Louis, MO, USA), 
was added at the beginning of the culture together with 
the VEGF-matured DCs.
After four days in culture, lymphocyte prolifera-
tion was monitored for the CD3+ population using KI-
67 nuclear staining as a proliferation marker. The lym-
phocytes were gated based on SSC vs. FSC, followed 
by CD3+ gating; the selected events were analysed in a 
second plot for KI-67 expression.
RNA isolation and quantitative real-time polymerase 
chain reaction (qPCR) - Monocytes, immature DCs and 
mature DCs were cultured in the presence or absence 
of VEGF for subsequent RNA isolation. Total RNA was 
isolated using the kit RNeasy® Mini Kit (Qiagen, Ger-
many).
The extracted RNA was then reverse transcribed into 
cDNA using oligo, dNTPmix and reverse transcriptase 
from the SuperScript® II Reverse Transcriptase kit (In-
vitrogen). The primers were based on the Homo sapiens 
gene sequences for IDO and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) obtained in the GenBank da-
tabase (ncbi.nlm.nih.gov).
The primers were designed using Primer-select 
(DNAstar Inc, USA) and were synthesised by Invitrogen 
as IDO (forward, 5’-GGCAACCCCCAGCTATCAGA-3’; 
reverse, 5’-CAGGGAGACCAGAGCTTTCACA-3’) and 
GAPDH (forward, 5’-GGAGAAGGCTGGGGCTCAT-3’; 
reverse, 5’-GTCCTTCCACGATACCAAAGTT-3’). The 
qPCR was performed using the Quanti Tect SYBR green 
PCR kit according to the manufacturer’s instructions 
(Qiagen, Germany). The data were acquired and analysed 
using an ABI7500 sequence detection system. The qPCR 
data were analysed by normalising the cycle threshold 
(Ct) values of the gene of interest to the Ct values of the 
housekeeping gene GAPDH (Livak & Schmittgen 2001). 
The results are displayed showing monocytes as the base-
line for comparison.
Ultrastructural characterisation by transmission 
electron microscopy (TEM) - The ultrastructures of 
monocytes and mature DCs grown in presence or ab-
sence of VEGF was examined by TEM.
The pellets of these cells were fixed in 0.2 M cacody-
late buffer with 1% glutaraldehyde for 2 h at 48ºC. The 
cells were then washed in cacodylate buffer twice for 15 
min each. Post-fixation was performed with 1% osmium 
tetroxide for 1 h at 48ºC, followed by washing for 15 min 
in the same buffer.
For contrast, the pellet was immersed in a solution of 
uranyl acetate for 30 min. After dehydration, the mate-
rial was embedded in Epon resin diluted in acetone (1:1) 
and incubated at 48ºC for 24 h with agitation.
The pellet was then transferred to pure Epon resin and 
incubated at 60ºC for 72 h until completely polymerised. 
Semi and ultrathin sections were obtained with a Porter 
Blum ultramicrotome.
The semithin sections were stained with Azure II 
(1%) and methylene blue (1%). The ultrathin sections 
were placed on copper grids and stained with uranyl 
acetate and citrate. The grids were observed and photo-
graphed using TEM (Philips CM100).
Statistical analysis - Statistical analyses were per-
formed by employing a two-tailed Student t test, with 
statistical significance set at a p-value ≤ 0.05. The Bon-
ferroni correction was used when necessary.
RESULTS
DC phenotypes after maturation induced PG-TNF 
or BCG - The differentiation of monocytes into DCs was 
assessed according to the expression of markers on D6 
of culture in comparison to that of the original monocyte 
population at the start of the culture (D0).
The expression of maturation markers was determined 
one day after the maturation stimuli were added to the six-
day-old cultures (D7). The frequencies of CD14+ popula-
tions on D0, D6 and D7 are shown in Fig. 1. The starting 
monocyte-enriched population was 82% CD14+ (Fig. 1A) 
(D0). After six days of culture in the presence of IL-4 + 
GM-CSF, the frequency of CD14+ cells had markedly de-
creased (Fig. 1A) (D6) and was maintained at low levels 
in either the PG + TNF or BCG-matured DCs (D7) (Fig. 
1A). In contrast, CD209, a marker exclusively expressed 
on DCs (Geijtenbeek et al. 2000), was not observed on D0, 
but was found in nearly 90% of the cells on D6 and its fre-
quency was maintained in the matured DCs (Fig. 1B). No 
differences in the frequency of cells expressing CD11c or 
HLA-DR were detected when comparing the cells at the 
D0, D6 and D7 stages of culture (Fig. 1C, D); however, the 
mean fluorescence index (MFI) showed increases on the 
order of two-three-fold. Significant increases in the fre-
quency of CD123+ cells were also observed as the mono-
cytes differentiated into DCs and subsequently matured 
(Fig. 1E) (D0 vs. D6 vs. D7). Taken together, these results 
indicate that the phenotypic differentiation of monocytes 
into DCs occurred in vitro.
DC maturation was evidenced by increases in the 
frequency and expression of the co-stimulation molecule 
CD80 and the maturation marker CD83 from D0-D6 and 
D7. In contrast, the MFI value of the co-stimulation mol-
ecule CD86 increased from D0-D6 and further increased 
as the cells matured (D7), although the CD86+ cell fre-
quencies were maintained from D0-D7 (Fig. 1F-H). In 
general, treatment with PG + TNFα was more effective 
at promoting the maturation of DCs than BCG, as the 
MFIs and frequencies of cells expressing CD80, CD83 
and CD86 were lower after BCG treatment (Fig. 1F-H).
We also examined the monocytes and DCs for the 
presence of VEGFR and found that 90% of the mono-
cytes expressed VEGFR1, VEGFR2 or VEGFR3 (Fig. 
2A-C), However, among the differentiated DCs (D6), 
the frequency of cells positive for each receptor fell to 
approximately 30%, as did the VEGFR1 and VEGFR3 
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Fig. 1A-H: expression of cell surface markers by human monocytes differentiated in vitro to dendritic cells (DCs) and cultured in the presence 
of prostaglandin E2 + tumour necrosis factor alpha (PG-TNF) or Bacillus Calmette-Guérin (BCG) as maturation factors. Blood monocytes were 
isolated from peripheral blood mononuclear cells obtained from normal donors and cultured, day zero (D0), in the presence of rGM-CSF and 
recombinant interleukin four-six days to differentiate them to immature DC (D6) and further cultured for 24 h in PG-TNF or BCG (D7) as matu-
ration factors. The cell suspensions were initially sorted by side light scatter (SSC) vs. forward light scatter (FSC) to exclude debris. The means 
and standard deviation (of 5 independent experiments) of the frequencies of positive cells for the different markers are shown in the graphs and 
significant (p < 0.05) differences are indicated by an asterisk. The respective mean fluorescence intensities (MFI) for each fluorescent marker 
are shown as insets to each graph accompanied by its isotype-matched irrelevant fluorescent IgG control. 
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MFI (but not for VEGFR2). At 24 h after the addition 
of maturation stimuli, the mean frequency of cells ex-
pressing VEGFR1 increased to 50%, but this increase 
was only significant for PG + TNF and not for BCG. 
This result was most likely due to the greater intensity 
of the PG + TNF maturation stimulus and therefore its 
effect on the cells could be better observed and evalu-
ated (Fig. 2A).
VEGF stimulates IDO expression by DCs treated 
with PG + TNF - PG has been broadly used as a potent 
DC maturation factor and has been shown to induce IDO 
expression (Braun et al. 2005). IDO mRNA expression 
in monocytes is very low and the mean value was used 
as a baseline for the comparison of the values after dif-
ferentiation and maturation.
As the monocytes differentiated into immature DCs 
(D6), the IDO relative mRNA expression levels were 
not significantly altered (Fig. 3A). However, a 1,000-
fold increase in IDO mRNA expression was observed 
in DCs that had been matured with PG + TNF for 24 h 
(Fig. 3A) and the presence of VEGF in the maturation 
cultures further increased IDO mRNA expression (Fig. 
3A). This increase is best observed in Fig. 3B, in which 
the relative increases are presented on a linear scale. In-
deed, we found that VEGF stimulated 100% increases in 
IDO mRNA expression in mature DCs (D7 V vs. D7). 
When these cell populations were stained for IDO and 
analysed by flow cytometry, the frequency of the cells 
matured with VEGF was 30% higher than those culti-
vated without VEGF (Fig. 3C).
VEGF influence on the morphology of PG + TNF-
treated DCs, as revealed by TEM - Under TEM obser-
vation, the preparations of monocytes (D0) showed a 
predominance of regular, round-shaped cells containing 
ovoid nuclei with loose chromatin and evident nucleoli 
(Fig. 4A). The mature DCs that had been treated with 
PG + TNF were irregular and often star-shaped, exhib-
iting characteristic dendritic-like prolongments (Fig. 
4B, C). These cells also demonstrated ovoid-shaped nu-
clei with loose chromatin and nucleoli; in addition, the 
mitochondria and rough endoplasmic reticulum were 
well developed and few lysosomes were observed (Fig. 
4B-D). The morphology of the DCs treated with VEGF 
(in addition to PG + TNF) was not much different than 
the above-described features, although some cells dis-
played intense cytoplasmic vacuolation (Fig. 4E, F) as-
sociated with rough endoplasmic reticulum vesiculation 
(Fig. 4H); these changes were compatible with the initial 
senescent cell population.
Fig. 2: expression of vascular endothelial growth factor (VEGF) receptors during human dendritic cell differentiation and subsequent matura-
tion in the presence of prostaglandin E2 + tumour necrosis factor alpha (PG-TNF) or Bacillus Calmette-Guérin (BCG). Human peripheral blood 
monocytes were cultured and differentiated as described in the legend to Fig. 1. The mean frequencies and standard deviation (n = 5 independent 
experiments) of dendritic cell expressing VEGFR1 (A), VEGFR2 (B) or VEGFR3 (C) are shown in the graphs accompanied by the mean values 
of mean fluorescence intensities (MFI). Significant differences (p < 0.05) are indicated by an asterisk.
Fig. 3: effect of vascular endothelial growth factor (VEGF) during 
dendritic cell (DC) maturation on the relative expression of indoleam-
ine 2,3-dioxygenase (IDO) mRNA and on intracellular IDO content 
detected by flow cytometry. Human peripheral blood monocytes were 
cultured and differentiated until day six (D6) as described in the legend 
of Fig. 1. Maturation was carried out with prostaglandin E2 + tumour 
necrosis factor alpha (PG-TNF) in the presence of VEGF: D7 (V) or 
just PG-TNF (D7). A: IDO mRNA relative expression in logarithmic 
scale; B: data in linear scale (asterisk means significant difference at p 
< 0.05). For comparison, very low levels of IDO mRNA of immature 
DC (D6) compare to monocytes (baseline) and mature DC [D7: DC 
matured in the absence of VEGF; D7V: DC matured in the presence 
of VEGF (representative of 3 independent experiments)] are shown in 
A. The difference between D7V-D7 is better seem in B due to linear 
scale; C: flow cytometry data of mature DC stained for intracellular 
IDO accompanied by the mean fluorescence intensities (MFI) values; 
IgG1: fluorescein isothiocyanate-labelled isotype control. 
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VEGF effect on apoptosis in PG + TNF-treated DCs, 
as revealed by flow cytometry - The cell cultures matured 
with PG + TNF + VEGF showed an increased frequency 
of Annexin V+ cells (a sign of early apoptosis) by 24 h 
(DC7V) and 48 h (DC8V) in comparison to cells cul-
tured in the absence of VEGF (Fig. 5A). In addition, late 
apoptosis or necrosis was also evidenced in the VEGF-
treated cultures after 48 h, as shown by higher frequen-
cies of double staining for Annexin and PI (DC8V) (Fig. 
5B, C). These data were also confirmed for late apopto-
sis, as a higher frequency of cells were positive for active 
caspase-3 (DC8V) (Fig. 5D). These results suggest that 
VEGF enhanced the apoptosis of DCs when present dur-
ing the maturation process and were in agreement with the 
ultrastructural changes described for these cell cultures.
DCs exposed to VEGF during maturation are less ca-
pable of inducing Ag-specific or mitogen-triggered lym-
phocyte proliferation - To determine whether the changes 
observed in VEGF-exposed DCs (e.g., IDO over-expres-
sion and accelerated apoptosis/senescence) would also 
translate into functional alterations, we next assessed Ag-
specific and PHA-triggered lymphocyte proliferation.
To this end, we employed a 2 x 2 factorial design 
in which we examined the level of autologous lympho-
cyte proliferation in the presence of DCs treated or not 
with VEGF. We used two independent stimuli, a specific 
stimulus dependent on presentation (C. albicans) and a 
non-specific mitogen, PHA, for four days of culture. 
We also repeated the experiment with PHA, evaluating 
lymphocyte proliferation by Ki-67 expression. To assess 
the effect of IDO on the maturation step, the DCs were 
matured in the presence of PG + TNF + VEGF and the 
IDO-inhibitor 1-MT was simultaneously added to the 
cultures; the resulting DC population was then tested in 
proliferation assays.
The VEGF-treated DCs caused a reduction in lym-
phocyte proliferation in response to Candida (Fig. 
6A-C) and PHA (Fig. 6D-F) in comparison to the DCs 
matured in the absence of VEGF. This result was further 
confirmed by a reduction in lymphocyte proliferation 
to PHA according to Ki-67 expression (Fig. 7D, E). Of 
note, the addition of 1-MT to VEGF-treated DCs gener-
ated DCs that were as affective as DCs matured without 
VEGF (Fig. 7D, F), indicating that the impaired prolifer-
ation observed in the co-cultures of VEGF-treated DCs 
and lymphocytes was related to the activation of the IDO 
pathway during the maturation phase.
DISCUSSION
Although it is well known that VEGF affects DC 
maturation, our results demonstrate for the first time 
that VEGF increases the expression and activity of IDO, 
which has a suppressive effect on Ag-specific and mito-
gen-stimulated lymphocyte proliferation.
BCG was originally used as a maturation factor be-
cause of its similarity to LPS and because it was already 
in use as a human therapy. However, we observed that 
PG + TNF induced a more robust phenotype than BCG 
in DC maturation; thus, we used only PG + TNF in these 
experiments. Because we did not use BCG in the ensu-
ing steps, these evaluations are valid for inflammatory 
environments, but are not necessarily relevant to infec-
tious pathways.
PGE2 has been shown to induce IDO expression 
(Munn et al. 1998); furthermore, TNF-α in combination 
with PG induces IDO activity during DC maturation 
(Trinchieri 1995, Braun et al. 2005). IDO-expressing 
DCs are considered to be immunological tolerance in-
ducers because they suppress lymphocyte activation 
and proliferation (Munn et al. 1998). Although PGE2 
induces IDO mRNA expression through its receptor E-
prostanoid 2 (EP2), enzyme activation is dependent on 
a second signal provided by TNFR or by TLR ligands 
(Braun et al. 2005). In contrast to these findings, it was 
reported that the induction of IDO expression by PGE2 
occurs through its receptor EP4 instead of EP2 and that 
PGE2-matured DCs were more capable of inducing both 
allogeneic and Ag-specific T cell proliferation when 
Fig. 4: transmission electron micrographs of monocytes and of den-
dritic cells (DCs) matured with prostaglandin E2 + tumour necrosis 
factor alpha (PG-TNF) in the presence or absence of vascular en-
dothelial growth factor (VEGF). Monocytes and mature DCs were 
obtained as described in the legend of Fig. 3. A: monocyte culture 
on day zero; B-D: DCs matured in PG-TNF (D7); E-H: DCs matured 
in PG-TNF + VEGF (D7V); c: cytoplasm; cp: cytoplasmic prolonga-
tions; li: lysossome; mi: mitochondria; mt: microtubule; n: nuclei; nu: 
nucleoli; rer: rough endoplasmic reticulum; v: vacuolation. 
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Fig. 5: effect of vascular endothelial growth factor (VEGF) on the expression of early and late markers of apoptosis and/or necrosis by dendritic 
cell (DC) cultures. The cells were cultured as described in legend of Fig. 3 with the maturation step carried out for 24 h with prostaglandin E2 
+ tumour necrosis factor alpha in the presence (DC7V) of VEGF or in its absence (DC7). In additional cultures the maturation step was carried 
out for 48 h in similar conditions, identified respectively as DC8V and DC8. The cells were double-stained for Annexin V/propidium iodide 
(apoptosis and/or necrosis) or stained only for caspase-3. A: cells that stained for Annexin V only (early apoptosis); B: cells double stained for 
Annexin V and propidium iodide only (late apoptosis/necrosis); C: frequencies of cells staining for Annexin V/PI + Annexin indicating the total 
number of cells undergoing apoptosis (early and late) and necrosis; D: cells expressing caspase 3 active (late apoptosis).
Fig. 6: T cell proliferation is impaired in the presence of dendritic cells (DCs) matured in the presence of vascular endothelial growth factor 
(VEGF) lymphocytes were co-cultivated with autologous DC that were treated with VEGF in addition to prostaglandin E2 + tumour necrosis 
factor alpha (PG-TNF) or only with PG-TNF during their maturation phase. Candida albicans was used to stimulate antigen-specific T lym-
phocyte proliferation (A-C). Histograms for lymphocytes labelled with side light scatter (SSC) vs. forward light scatter (FSC) are shown in B 
for co-cultures with PG-TNF-DC and in C for co-cultures with PG-TNF-V-DC. A: respective calculated indexes of cell division; D: respective 
calculated indexes of cell division for phytohemagglutinin (PHA)-stimulated cultures; D-F: PHA was used as T-cell mitogen; E, F: histograms 
of CFS-labelled lymphocytes co-cultured with DC matured without (E) or with VEGF (F). Asterisk means significant difference at p < 0.05.
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compared to DCs matured in the absence of this mol-
ecule (Krause et al. 2007). More recently (Lanzinger 
et al. 2012), it was shown that the stimulatory effect of 
PGE2-matured DCs on allogeneic T cells is variable and 
may be highly context dependent. When the IDO activ-
ity in the microenvironment is low, DCs act as effective 
stimulators of immune responses; however, once the en-
zymatic activity of IDO predominates, these cells sup-
press T cell responsiveness and/or promote regulatory T 
cell responses.
Because of the importance of IDO as a regulator of 
immune responses and the ubiquitous presence of VEGF 
in tumoural or inflammatory microenvironments, it was 
of interest to investigate whether VEGF would affect 
IDO expression by DCs. Indeed, our results show that 
IDO expression by DCs was significantly increased in 
the presence of VEGF compared to untreated DCs. In 
fact, both PG-TNF and VEGF contributed to augment 
IDO expression, suggesting a synergistic effect. Corrob-
orating these data, we also observed that the induction 
of DC maturation by PG + TNFα significantly increased 
the expression of VEGFR1, thereby facilitating synergic 
signalling by VEGF (Dikov et al. 2005).
Our data concerning the ultrastructure of DCs 
treated with VEGF revealed morphological changes, 
predominantly vacuolation, which were compatible 
with processes that ultimately lead to cell death. This 
was further confirmed by Annexin V/propidium iodide 
staining of VEGF-treated DCs, which is indicative of 
apoptosis/necrosis (Henics & Wheatley 1999, Orabona 
et al. 2008). The accelerated apoptosis of VEGF-treated 
DCs was most likely caused by a combination of factors. 
First, as has been previously shown, PG can stimulate 
programmed cell death by inducing the pro-apoptotic 
protein Bax (Lalier et al. 2011); second, VEGF acting in 
synergy would most likely further enhance apoptosis. In 
addition, tryptophan is an amino acid that is essential to 
cell survival and IDO activation reduces its availability 
to the cell (Broker et al. 2005).
One important question, however, was how DCs 
exposed to VEGF would function as regulators of the 
immune response. We found that specific (C. albicans) 
and mitogen-induced (PHA) lymphocyte proliferation 
were reduced in the presence of VEGF-treated DCs. 
This effect was due to IDO activity, as confirmed by 
experiments in which the addition of a specific IDO 
inhibitor (1-MT) during the maturation of VEGF-DCs 
completely abolished their suppressive activity on lym-
phocyte proliferation.
Another mechanism by which DCs develop an im-
munosuppressive phenotype is the ingestion of apop-
totic cells (da Costa et al. 2011). However, because the 
DCs added to the co-cultures were mature and also 
γ-irradiated, their phagocytic activity was much re-
duced; thus, it is unlikely that such a mechanism was 
important to the observed suppression of lymphocyte 
proliferation in our assays. In addition, phagocytosis of 
apoptotic cells was not observed in our TEM examina-
tion of sections of VEGF-matured DCs.
Taken together, our results suggest that VEGF plays 
a role in the complex process of immunological toler-
ance, as it can stimulate DCs to over-activate the IDO 
pathway. The ensuing tryptophan depletion leads to the 
inhibition of T cell activation and expansion (Grohmann 
& Bronte 2010, Kushwah & Hu 2010). In addition, DCs 
that express IDO can stimulate the cellular general con-
trol non-depressible 2 kinase-dependent stress response 
in naïve and mature T cells and in functionally quiescent 
T regulatory cells, leading to active bystander suppres-
sion (Fallarino et al. 2006, Sharma et al. 2007).
These mechanisms have broad implications in the 
study of immunological responses and tolerance under 
conditions as diverse as cancer, graft rejection and au-
toimmunity.
Fig. 7: addition of the inhibitor 1-methyl-D-tryptophan (1-MT) of in-
doleamine 2,3-dioxygenase (IDO) prevents vascular endothelial growth 
factor (VEGF)-matured dendritic cell (DC) from suppressing lympho-
cyte proliferation. T cell proliferation stimulated by phytohemaggluti-
nin (PHA) was estimated by flow-cytometry of CD3+ lymphocytes ex-
pressing the antigen KI-67 (A) lymphocytes gated on side light scatter 
(SSC) vs. forward light scatter (FSC) (B), histogram of gated CD3+ cells 
(C), KI-67 expression on CD3+ lymphocytes without stimuli (1.56% of 
the cells express the marker) (D), KI-67 expression on PHA-stimulated 
CD3+ lymphocytes co-cultured with autologous DC matured without 
VEGF (frequency of positive cells - 37.4%) (E), KI-67 expression on 
PHA-stimulated CD3+ lymphocytes co-cultured with autologous DC 
matured with VEGF (frequency of positive cells - 17.6%) and KI-67 
expression on PHA-stimulated CD3+ lymphocytes co-cultured with au-
tologous DC matured with VEGF in the presence of 1-MT as inhibitor 
of IDO (frequency of positive cells - 35%) (representative of 3 indepen-
dent experiments) (F). FITC: fluorescein isothiocyanate.
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